398 related articles for article (PubMed ID: 36980677)
1. The BAFF-APRIL System in Cancer.
Ullah MA; Mackay F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980677
[TBL] [Abstract][Full Text] [Related]
2. Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta.
Langat DL; Wheaton DA; Platt JS; Sifers T; Hunt JS
Am J Pathol; 2008 May; 172(5):1303-11. PubMed ID: 18403603
[TBL] [Abstract][Full Text] [Related]
3. The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.
Kampa M; Notas G; Stathopoulos EN; Tsapis A; Castanas E
Front Oncol; 2020; 10():827. PubMed ID: 32612943
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
5. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
7. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
8. CD256 can be found in antibody-mediated renal allograft rejection tissues.
Xu H; He X; Zhao W; Guo H; Shi Q; Zhu Y; Zhang X
Clin Lab; 2012; 58(5-6):411-8. PubMed ID: 22783569
[TBL] [Abstract][Full Text] [Related]
9. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
[TBL] [Abstract][Full Text] [Related]
10. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.
Alexaki VI; Notas G; Pelekanou V; Kampa M; Valkanou M; Theodoropoulos P; Stathopoulos EN; Tsapis A; Castanas E
J Immunol; 2009 Nov; 183(9):5948-56. PubMed ID: 19828625
[TBL] [Abstract][Full Text] [Related]
11. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.
Ferrer G; Bosch R; Hodgson K; Tejero R; Roué G; Colomer D; Montserrat E; Moreno C
Br J Haematol; 2014 Feb; 164(4):570-8. PubMed ID: 24245956
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
[TBL] [Abstract][Full Text] [Related]
13. Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma.
Birnbaum T; Langer S; Roeber S; von Baumgarten L; Straube A
Neurol Int; 2013 Feb; 5(1):e4. PubMed ID: 23717783
[TBL] [Abstract][Full Text] [Related]
14. Expression of TNF-α, APRIL and BCMA in Behcet's disease.
Shaker OG; Tawfic SO; El-Tawdy AM; El-Komy MH; El Menyawi M; Heikal AA
J Immunol Res; 2014; 2014():380405. PubMed ID: 25759827
[TBL] [Abstract][Full Text] [Related]
15. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
16. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.
Mackay F; Schneider P
Cytokine Growth Factor Rev; 2008; 19(3-4):263-76. PubMed ID: 18514565
[TBL] [Abstract][Full Text] [Related]
17. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
18. The BAFF/APRIL system: life beyond B lymphocytes.
Ng LG; Mackay CR; Mackay F
Mol Immunol; 2005 May; 42(7):763-72. PubMed ID: 15829264
[TBL] [Abstract][Full Text] [Related]
19. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
20. LT-K63 Enhances B Cell Activation and Survival Factors in Neonatal Mice That Translates Into Long-Lived Humoral Immunity.
Aradottir Pind AA; Molina Estupiñan JL; Magnusdottir GJ; Del Giudice G; Jonsdottir I; Bjarnarson SP
Front Immunol; 2020; 11():527310. PubMed ID: 33193301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
